Hepatic Disease in HIV-Infected Patients
Summary
- Treatment of Insulin Resistance
- Improving systemic insulin resistance may be beneficial but is not sufficient to prevent progression of fatty liver disease
- US and European guidelines support reserving the use of pharmacotherapy for treatment of insulin resistance to patients with NASH or fibrosis[AASLD NAFLD; EASL NAFLD]
- Studies of hydroxymethylglutaryl-CoA reductase inhibitors (statins) have reported some evidence of reductions in serum ALT[Gómez-Domínguez 2006; Hatzitolios 2004; Athyros 2006; Abel 2009]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content